Skip to content

HELP-HY: Health Education and sLeep Program in HYpertension

HELP-HY: Health Education and sLeep Program in HYpertension

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03255746
Enrollment
110
Registered
2017-08-21
Start date
2018-04-19
Completion date
2025-03-20
Last updated
2026-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Prehypertension

Brief summary

Hypertension is the major risk factor for cardiovascular and cerebrovascular diseases worldwide. The escalating prevalence of inadequate sleep now parallels that of hypertension. Observational and experimental evidence favoring a causal relation between insufficient sleep and hypertension are particularly compelling - sleeping 6 hours or less per night is associated with a 20-32% higher probability of incident hypertension. Since sleep curtailment is largely voluntary, sleep deficiency may be corrected and the detrimental health consequences potentially reversed. In this study the investigators aim to investigate the effects of 8 weeks of sleep enhancement/extension vs health education in prehypertensive and stage 1 hypertensive subjects who report habitual short sleep (≤6.5 hours/night).

Interventions

BEHAVIORALSleep Enhancement

This regimen combines education and behavioral skills to enable prolonging sleep in chronically sleep deprived subjects so as to better meet participant's sleep needs. This intervention emphasizes plain language communication of cognitive behavioral therapy strategies for initiating and maintaining health behavior change, primarily through using brief action plans (time-limited, personally relevant, behavioral goal setting with confidence), and collaborative problem-solving. Coaching will be provided to modify daily routines and adhere to sleep hygiene practices to allow for extended time in bed.

BEHAVIORALHealth Education

This is a placebo/attention control condition. Participants will receive health education based on NIH information. Number, duration, and frequency of sessions will be identical to those administered to the intervention group.

Sponsors

Mayo Clinic
Lead SponsorOTHER
National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Age: 18 to 65 (inclusive) * Gender: both males and females * Body mass index (BMI): 18.5-34.9 kg/m2 * Habitual sleep duration \<7 hours and voluntary prolongation of sleep when circumstances allow (as indicated by napping and/or \>45 min catch-up sleep during weekends or holidays) * Presence of prehypertension (office systolic BP (SBP) 120-139 mmHg and/or diastolic BP (DBP) 80-89 mmHg) , Stage 1 hypertension (office SBP 140-159 mmHg and/or DBP 90-99 mmHg ) , or currently taking antihypertensive medications * Either on no prescription medications (other than oral contraceptive pills, or intrauterine devices) or on stable medical regimen for at least 1 month, if taking prescription medications for chronic conditions * Not pregnant or breast feeding and not intending to become pregnant or breast feed * Not a current smoker or tobacco user * Ability to provide written informed consent.

Exclusion criteria

* Vulnerable study populations will be excluded * Pregnancy * Smoking * Shift-work * Travel across \>2 time zones in the previous month * Presence of overt cardiovascular diseases, diabetes, chronic kidney disease, cancer, sleep/circadian disorders, psychiatric disorders * If taking prescription medications for chronic conditions, change in therapy (type, frequency and/or dosage) over the previous month * Sleep aids * Habitual sleep duration ≥7 hours * Excessive alcohol (\>14 drinks/week in men and \>7 drinks/week in women) and/or excessive caffeine intake (\>400 mg) * Currently on a diet and/or actively trying to lose weight * History of drowsing driving * Severe daytime sleepiness (score \>15 at the Epworth Sleepiness Scale) * Current or previous (during the past 2 months) participation in other research studies at the discretion of study personnel * Blood/plasma donation during the past 2 months * Unwillingness or inability to adjust sleep schedule

Design outcomes

Primary

MeasureTime frameDescription
change in 48-hour mean arterial pressure8 weekschanges in ambulatory measure of blood pressure

Secondary

MeasureTime frameDescription
changes in 48-hour heart rate8 weekschanges in 24-hour heart rate
changes in baroreflex sensitivity8 weekschanges in baroreflex sensitivity
changes in endothelial function8 weekschanges in endothelial function
changes in renin8 weekschanges in renin
changes in angiotensin peptides8 weekschanges in angiotensin peptides
changes in aldosterone8 weekschanges in aldosterone
changes in insulin sensitivity8 weekschanges in insulin sensitivity
changes in cortisol8 weekschanges in cortisol
changes in body fat8 weekschanges in body fat
changes in catecholamines8 weekschanges in catecholamines

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORVirend Somers, MD, PhD

Mayo Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 17, 2026